Trials Open to Enrollment

AIDS Clinical Trials: New Trials Open to Enrollment

http://www.actis.org/actinewl.html

14AA11tyd1Li1 11&Ji i %15i V~f iJ33. 1 )A111 *J1 v 1 i 1i.J iZU1Jk V A V i 1 4. P F2.VJ A.24S RJ6Ra1~1 %#A l.-2P
Q Effects of Treatment for MAC Infection on Cytokine Expression in HIV-infected Persons.
NIAID ACTG 853
The purpose of this AIDS Clinical Trials Group study is to determine if treatment of MAC
infection in HIV-1 infected persons is associated with the decreases in plasma levels of TNF-alpha.
For more information, view the Protocol Database record.
SA Randomized, Parallel, Open-Label Phase I Study of LXR015-1 in HIV-Infected Patients.
FDA 258A. Drug: LXR015-1.
The purpose of this LXR Biotechnology Inc. study is to determine and compare the safety and
tolerability of 3 doses of LXRO15-1 in HIV-infected patients. For more information, view the
Protocol Database record.
E A Phase I Double-Blinded Trial Of Recombinant Human Interleukin-12 (rhlL-12) In
HIV-Infected Subjects With Less Than 50 CD4+ T Cells And Subjects With 300-500 CD4+
T Cells, Who Have No Evidence Of Serious Ongoing Opportunistic Infections. NIAID ACTG
325. Drug: Interleukin-12.
The purpose of this AIDS Clinical Trials Group study is to determine the tolerance of
asymptomatic HIV-1 infected volunteers to rising, multiple doses of CI-1012, a zinc finger
inhibitor and to assess the multiple-dose pharmacokinetics characteristics of CI-1012. To determine
the antiretroviral activity on CD4+ T cell count of CI-1012 in asymptomatic HIV-1 infected
patients. For more information, view the Protocol Database record.
E A Phase I Multiple Oral, Rising Dose, Tolerance and Pharmacokinetics Trial of CI-1012 in
HIV-1 Infected Volunteers. NIAID 97 1-032. Drug: CI-1012.
The purpose of this National Institute of Allergy & Infectious Diseases sponsored study is to
determine the tolerance of asymptomatic HIV-1 infected volunteers to rising, multiple doses of
CI-1012, a zinc finger inhibitor and to assess the multiple-dose pharmacokinetics characteristics of
CI-1012. To determine the antiretroviral activity on CD4+ T cell count of CI-1012 in
asymptomatic HIV-1 infected patients. For more information, view the Protocol Database record.
E A Randomized Trial of the Efficacy and Safety of Nelfinavir Versus Ritonavir Added to
Background Antiretroviral Nucleoside Therapy in HIV-Infected Individuals With CD4+
Cell Counts <= 100/mm3. NIAID CPCRA 042 Drugs: Ritonavir, Nelfinavir.
The purpose of this Community Programs for Clinical Research on AIDS sponsored study is to
compare Nelfinavir (NFV) with Ritonavir (RTV) for delaying disease progression or death in
HIV-infected patients with CD4+ cell counts less than 100 cells/mm3. To compare NFV with RTV
for the development of adverse events and for rates of permanent discontinuation of study
medication. For more information, view the Protocol Database record.
E An Exploratory Study of the Antiretroviral Activity of 1592U89 When Administered in
Combination With Other Specific Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in
NRTI Experienced Patients. FDA 238C. Drug: 1592U89.

5of 10

03/17/97 15:06:53